BACKGROUND: Age-related risk of medullary thyroid carcinoma (MTC) development in presymptomatic carriers of lower risk germline RET mutations is uncertain; such data may aid counseling patients regarding timing of thyroidectomy. METHODS: From an institutional database and an exhaustive literature review, we identified 679 patients with American Thyroid Association (ATA) level A or B mutations who were identified because of family screening (index cases of MTC were excluded to minimize selection bias). We evaluated age at thyroidectomy or last evaluation if no thyroidectomy, preoperative calcitonin level (elevated or not), the mutated codon, and outcome (MTC vs. no MTC after thyroidectomy or no clinical evidence of MTC if thyroid intact). Data were used to estimate the cumulative prevalence of MTC and/or assess likelihood of MTC stratified by codon. After exclusion of cases with missing data or small representation, 503 patients with mutations in codons 533, 609, 611, 618, 620, 791, and 804 were analyzed. RESULTS: 236 patients had MTC. Cumulative prevalence and median time to MTC varied by codon and within ATA risk levels (p<0.0001). Patients with a codon 620 mutation were 2.8-6.9 times more likely to have MTC than other level B mutation carriers, and 5.1-21.7 times more likely than level A mutation carriers included in our focus population. The youngest median time to MTC was 19 years for codon 620 and the oldest was 56 years for codon 611. Cumulative prevalence of MTC by age 20 was 10% or lower for codons 533, 609, 611, 791, and 804. By age 50, it ranged from 18% for codon 791 to 95% for codon 620. An elevated preoperative calcitonin level strongly predicted MTC on final pathology, though false-negative rates varied by codon (p<0.0001). Positive predictive values ranged from 76% to 100% by codon with an overall positive predictive value of 87% across codons. CONCLUSIONS: This study offers a better understanding of the age-related development of MTC in lower risk RET mutation carriers, provides evidence of further distinctions between lower risk mutations within ATA subgroups, and clarifies the clinical significance of codon 791 mutations. The data support individualized "codon-based" management approaches coupled with clinical data such as calcitonin levels.
BACKGROUND: Age-related risk of medullary thyroid carcinoma (MTC) development in presymptomatic carriers of lower risk germline RET mutations is uncertain; such data may aid counseling patients regarding timing of thyroidectomy. METHODS: From an institutional database and an exhaustive literature review, we identified 679 patients with American Thyroid Association (ATA) level A or B mutations who were identified because of family screening (index cases of MTC were excluded to minimize selection bias). We evaluated age at thyroidectomy or last evaluation if no thyroidectomy, preoperative calcitonin level (elevated or not), the mutated codon, and outcome (MTC vs. no MTC after thyroidectomy or no clinical evidence of MTC if thyroid intact). Data were used to estimate the cumulative prevalence of MTC and/or assess likelihood of MTC stratified by codon. After exclusion of cases with missing data or small representation, 503 patients with mutations in codons 533, 609, 611, 618, 620, 791, and 804 were analyzed. RESULTS: 236 patients had MTC. Cumulative prevalence and median time to MTC varied by codon and within ATA risk levels (p<0.0001). Patients with a codon 620 mutation were 2.8-6.9 times more likely to have MTC than other level B mutation carriers, and 5.1-21.7 times more likely than level A mutation carriers included in our focus population. The youngest median time to MTC was 19 years for codon 620 and the oldest was 56 years for codon 611. Cumulative prevalence of MTC by age 20 was 10% or lower for codons 533, 609, 611, 791, and 804. By age 50, it ranged from 18% for codon 791 to 95% for codon 620. An elevated preoperative calcitonin level strongly predicted MTC on final pathology, though false-negative rates varied by codon (p<0.0001). Positive predictive values ranged from 76% to 100% by codon with an overall positive predictive value of 87% across codons. CONCLUSIONS: This study offers a better understanding of the age-related development of MTC in lower risk RET mutation carriers, provides evidence of further distinctions between lower risk mutations within ATA subgroups, and clarifies the clinical significance of codon 791 mutations. The data support individualized "codon-based" management approaches coupled with clinical data such as calcitonin levels.
Authors: William B Kinlaw; Sarah M Scott; Robert A Maue; Vincent A Memoli; Robert D Harris; Gilbert H Daniels; Donna M Porter; Dorothy R Belloni; Edward T Spooner; Manfred M Ernesti; Walter W Noll Journal: Clin Endocrinol (Oxf) Date: 2005-12 Impact factor: 3.478
Authors: G L Feldman; M W Edmonds; P J Ainsworth; I Schuffenecker; G M Lenoir; A W Saxe; G B Talpos; J Roberson; N Petrucelli; C E Jackson Journal: Surgery Date: 2000-07 Impact factor: 3.982
Authors: M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: A Nakao; Y Naomoto; M Kataoka; M Haisa; K Kataoka; S Saitoh; T Fujiwara; T Yamatsuji; K Shigemitsu; T Umeoka; H Isozaki; H Futami; K Yamaguchi; N Tanaka Journal: Jpn J Clin Oncol Date: 2001-04 Impact factor: 3.019
Authors: Jonathan D Wasserman; Gail E Tomlinson; Harriet Druker; Junne Kamihara; Wendy K Kohlmann; Christian P Kratz; Katherine L Nathanson; Kristian W Pajtler; Andreu Parareda; Surya P Rednam; Lisa J States; Anita Villani; Michael F Walsh; Kristin Zelley; Joshua D Schiffman Journal: Clin Cancer Res Date: 2017-07-01 Impact factor: 12.531
Authors: Rodrigo A Toledo; Roxanne Hatakana; Delmar M Lourenço; Susan C Lindsey; Cleber P Camacho; Marcio Almeida; José V Lima; Tomoko Sekiya; Elena Garralda; Michel S Naslavsky; Guilherme L Yamamoto; Monize Lazar; Osorio Meirelles; Tiago J P Sobreira; Maria Lucia Lebrao; Yeda A O Duarte; John Blangero; Mayana Zatz; Janete M Cerutti; Rui M B Maciel; Sergio P A Toledo Journal: Endocr Relat Cancer Date: 2014-11-25 Impact factor: 5.678
Authors: S I Sherman; R T Kloos; R M Tuttle; A Pontecorvi; H Völzke; K Harper; C Vance; J T Alston; A L Usborne; K W Sloop; M Lakshmanan Journal: Diabet Med Date: 2018-03 Impact factor: 4.359
Authors: Michelle L Thompson; Candice R Finnila; Kevin M Bowling; Kyle B Brothers; Matthew B Neu; Michelle D Amaral; Susan M Hiatt; Kelly M East; David E Gray; James M J Lawlor; Whitley V Kelley; Edward J Lose; Carla A Rich; Shirley Simmons; Shawn E Levy; Richard M Myers; Gregory S Barsh; E Martina Bebin; Gregory M Cooper Journal: Genet Med Date: 2018-04-12 Impact factor: 8.822